Pharming Group (PHGUF) Stock Price, News & Analysis

Company Overview

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Key Stats

• Today's Range: $0.90 to $0.90
• 50-Day Range: $0.79 to $0.94
• 52-Week Range: $0.75 to $1.07
• Volume: N/A
• Average Volume: 18,240 shs
• Market Capitalization: $603.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHGUF Stock Analysis - Frequently Asked Questions

How have PHGUF shares performed this year?

Pharming Group's stock was trading at $0.9815 at the beginning of 2025. Since then, PHGUF stock has decreased by 8.3% and is now trading at $0.90.
View the best growth stocks for 2025 here.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative trailing twelve-month return on equity of 7.65% and a negative net margin of 6.09%.

How do I buy shares of Pharming Group?

Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/05/2015
• Today: 4/04/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHGUF
• Previous Symbol: OTC:PHGUF
• CIK: N/A
• Web: www.pharming.com
• Phone: (171) 524-7400
• Fax: 31-0-71-524-7445
• Employees: 382
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,550,000.00
• Net Margins: -6.09%
• Pretax Margin: N/A
• Return on Equity: -7.65%
• Return on Assets: -3.82%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 3.53
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: $245.32 million
• Price / Sales: 2.46
• Cash Flow: $0.01 per share
• Price / Cash Flow: 89.78
• Book Value: $0.33 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 671,073,000
• Free Float: N/A
• Market Cap: $603.97 million
• Optionable: Not Optionable
• Beta: 0.91